Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vepafestinib (TAS0953/HM06)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Helsinn, Otsuka

Drug class:

RET inhibitor

Related drugs:

RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	TAS0953/HM06 Sensitive: C2 – Inclusion Criteria TAS0953 / HM06 Sensitive : C2	TAS0953/HM06 Sensitive: C2 – Inclusion Criteria TAS0953 / HM06 Sensitive : C2
TRIM33-RET fusion	Non Small Cell Lung Cancer	TRIM33-RET fusion	Non Small Cell Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D
SPECC1L-RET fusion	Sarcoma	SPECC1L-RET fusion	Sarcoma	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D
RET-KIF5B fusion	Lung Cancer	RET-KIF5B fusion	Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D
RET-TRIM33 fusion	Lung Cancer	RET-TRIM33 fusion	Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D
RET C634W	Thyroid Gland Medullary Carcinoma	RET C634W	Thyroid Gland Medullary Carcinoma	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D
RET-CCDC6 fusion	Lung Cancer	RET-CCDC6 fusion	Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D	TAS0953/HM06 Sensitive: D – Preclinical TAS0953 / HM06 Sensitive : D